Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...

Related Keywords

United States ,Melbourne ,Victoria ,Australia ,California ,San Francisco ,Daniel Claassen ,Hannah Howlett ,Paula Trujillo Diaz ,David Stamler ,Remy Bernarda ,Nasdaq ,European Commission ,Company Biomarkers ,Vanderbilt University Medical Center ,Department Of Neurology ,Research Assistant Professor ,System Atrophy National Institute Of Neurological Disorders ,Alterity Therapeutics ,Securities Exchange ,International Symposium ,Multiple System Atrophy ,Natural History Study ,Autonomic Nervous System ,Vanderbilt University Medical ,Chief Executive Officer ,Unified Multiple System Atrophy Rating Scale ,Natural History ,Parkinson Plus Syndromes ,System Atrophy ,Multiple System ,National Institute ,Neurological Disorders ,Media Contacts ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,